연말에 이노엔 다시 보면 되겠군요..

Channel
일타강사 ’제약/바이오‘ 투자 길라잡이
@K_biopharma1st
On this record: Topic · Growth · Engagement · Reactions · Posts · Citations · Cite this entry
4,621subscribers
-1 since we began measuring on 7 August 2026
Risers and fallers across the register · movement among entries of 3,162–10,000.
Register entry
| Telegram ID | -1002144600618 |
|---|---|
| Type | Channel |
| Username | @K_biopharma1st |
| Created | Between 1 November 2023 and 31 May 2024 — estimated from Telegram’s id allocation, not measured. How this range is calculated. |
| First recorded | 7 August 2026 |
| Last confirmed live | 15 September 2026 |
| Measurements held | 14 |
| Confirmed unchanged | 1 time, most recently 15 September 2026 |
| On Telegram | t.me/K_biopharma1st |
Topic
Other / unclassifiable — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 13 September 2026 and assigned it the closest of 31 fixed categories, at 54% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and why it has no browse page of its own yet.
Growth
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 15 Sept 2026, 09:16 | 4,621 | -4 |
| 11 Sept 2026, 09:01 | 4,625 | -9 |
| 6 Sept 2026, 11:19 | 4,634 | +6 |
| 2 Sept 2026, 12:54 | 4,628 | -13 |
| 30 Aug 2026, 07:55 | 4,641 | +2 |
| 27 Aug 2026, 03:16 | 4,639 | -6 |
| 24 Aug 2026, 11:13 | 4,645 | +8 |
| 20 Aug 2026, 22:53 | 4,637 | +27 |
| 18 Aug 2026, 00:52 | 4,610 | -5 |
| 15 Aug 2026, 02:38 | 4,615 | -6 |
| 11 Aug 2026, 12:15 | 4,621 | -2 |
| 8 Aug 2026, 12:04 | 4,623 | +1 |
| 7 Aug 2026, 17:31 | 4,622 | no change |
| 7 Aug 2026, 17:25 | 4,622 | first reading |
Engagement
40 posts held, back to 7 August 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 6 pages of Telegram’s post history, 20 posts per page.
Nothing published in the last 30 days. ERR and ER are rolling 30-day measures, so there is nothing to compute — we hold 40 posts for this entry, the most recent from 12 August 2026. An engagement rate over an empty window would be a number about nothing.
Reaction mix
53 reactions across 15 posts, in 2 distinct kinds. The most used accounts for 71.7% of them.
| Reaction | Count | Share | Share, drawn |
|---|---|---|---|
| ❤ | 38 | 71.7% | |
| 👍 | 15 | 28.3% |
No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.
Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.
Coverage. Reactions were read on 17 of the 40 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 53 reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.
Measured over the 40 most recent posts we hold, published 7 August 2026 to 12 August 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.
Recent posts
P-CAB 제제 현황 잘 설명해둔 기사. HK이노엔-세벨라, 케이캡 미국 허가여부 내년 1월 결정 온코닉, 3상 IND 준비..2029년 시판 목표 대웅, 미 진출 검토
https://www.wowtv.co.kr/NewsCenter/News/Read?articleId=A202607300529
2026.08.12 13:52:18 기업명: 온코닉테라퓨틱스(시가총액: 6,539억) A476060 보고서명: 반기보고서 (2026.06) 잠정실적 : N 매출액 : 244억(예상치 : 234억, +4.3%) 영업익 : 28억(예상치 : 28억, -0.4%) 순이익 : 38억(예상치 : 28억, +34.6%) **최근 실적 추이** (기간/ 매출/ 영업익/ 순익) 2026.2Q 244억/ 28억/ 38억 2026.1Q 230억/ 46억/ 64억 2025.4Q 156억/ 16억/ 47억 2025.3Q 192억/ 83억/ 94억 2025.2Q 94억/ 11억/ -2억 공시링크: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260812000381
❤1
이런저런 공부 및 리스크가 싫으면...바이오에서도 액티브바이오 ETF가 좋죠. 소외는 안당하고..우량 바이오텍들 비중크게크게 매니저가 알아서 관리해주고요
❤2
암튼, 단기 조정 나오고 있는데...2차 랠리를 위한 필수적인 과정으로 생각합니다. 그간 너무 노답으로 빠져서...
시간이 오래 걸리기에...바이오만 하면 타섹터 갈때 포모도 이겨내야하고요..
좋은 기업과 의미 있는 지점을 발견하고 → 투자한 뒤 → 모멘텀이 현실화될 때까지 기다리고 → 대시세를 함께하는 과정이라고 생각합니다. 매일의 등락에 지나치게 흔들리기보다 투자 근거가 훼손되지 않았는지 확인하면서 진득하게 하루하루 보내면 될 것 같습니다.
그래도 요즘 상장하는 기업들 보면...불과 5년전과 비교해도 엄청나게 달라졌음을 느낍니다..어디 릴리, GSK, 머크랑 딜을 상상이나 했었을까...
미국 바이오텍과는 완전히 다릅니다 국내는
결과값은 어지간하면 안까보고 기대감만 보고요
여러 투자방식 중 맞는것을 잘 선택해야 하는거고요...전 일정 보고 분할매수 후 대응하는 전략을 선호합니당..
Showing the 12 most recent of 40 posts we hold for @K_biopharma1st. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Forward network
Republished by
Channels on the register that have forwarded this channel's posts into their own feed.
Republishes
Channels on the register whose posts this channel has forwarded.
@stoner8740 · 11,0354 posts🧬바이오섹터 분석🧬 [그로쓰리서치]
@growthbio · 13,3592 posts[Public] 파이낸스 스코프
@FS_public_channel · 8451 post알테오젠 IR
@alteogenIR · 9,8001 postAWAKE - 실시간 주식 공시 정리채널
@darthacking · 65,0961 post한경바이오인사이트
@hkbioinsight · 4,2961 post제약/바이오/미용 원리버 Oneriver
@pharmbiohana · 29,8431 post스몰인사이트리서치
@smallinsightresearch · 5,7231 post더바이오 뉴스룸
@thebio111 · 6,5131 post
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
Mentions
Names
Channels on the register whose handles appear in this channel's posts.
A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.
Cite this entry
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 15 September 2026 — this entry's latest reading, not the date you are reading this.
“일타강사 ’제약/바이오‘ 투자 길라잡이” (@K_biopharma1st), 4,621 subscribers as measured 15 September 2026. Telegram Register, tgregister.com/channel/K_biopharma1st.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.